More biotechs join S&P300 index
Friday, 05 September, 2003
Market analyst Standard and Poor's has added four more Australian biotechnology firms and a medical device company to its S&P300 index.
Circadian Technologies, Genetic Technologies, Metabolic Pharmaceuticals and Norwood Abbey, along with retractable syringe specialist Unitract, will join the index from September 19.
Tim Eisenhauer, S&P's head of index services, said companies were selected to join the index on the basis if the free float of their shares, on their market capitalisation, and their liquidity over a six-month period.
The last healthcare firm to join the 300 was artificial heart maker Ventracor.
The S&P300's healthcare board also includes Agenix, Cellestis, Chemeq, Cochlear, CSL, IDT, Novogen, Peptech, ResMed and Sirtex.
New route into cells found for gene therapy viruses
Scientists have identified a previously unknown gateway into human cells — a receptor...
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
